LONDON-- GlaxoSmithKline PLC (GSK.LN) said Tuesday that it and Merck & Co. Inc. (MRK) will trial a combination of two separate drugs as a potential cancer treatment.

The companies will commence human trails to evaluate Glaxo's investigational immunotherapy GSK3174998 as monotherapy in combination with Merck's anti-PD-1 therapy Keytruda in patients with tumors that have progressed after standard treatment.

Shares of Glaxo at 1227 GMT trading 0.04% lower at 1,397 pence.

Write to Tapan Panchal at tapan.panchal@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

November 03, 2015 07:45 ET (12:45 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.